Literature DB >> 18268214

Microglial activation in human diabetic retinopathy.

Hui-yang Zeng1, William Richard Green, Mark O M Tso.   

Abstract

OBJECTIVE: To investigate microglial activation in human diabetic retinopathy.
METHODS: Paraffin sections from 21 eyes of 13 patients with diabetic background, preproliferative, or proliferative retinopathies and 10 normal eyes of 9 individuals were studied with immunolabeling of microglia with antibodies against HLA-DR antigen, CD45, or CD68.
RESULTS: In the healthy human eyes, ramified microglial cells were scattered in the inner retinal layers. In eyes with diabetic retinopathy, the microglia were markedly increased in number and were hypertrophic at different stages of the disease. These cells clustered around the retinal vasculature, especially the dilated veins, microaneurysms, intraretinal hemorrhages, cotton-wool spots, optic nerve, and retinal and vitreal neovascularization. In some retinas with cystoid macular edema, microglia infiltrated the outer retina and subretinal space. Cells in the epiretinal membrane were also labeled with microglial markers.
CONCLUSIONS: Microglia were activated at different stages of human diabetic retinopathy and optic neuropathy. Microglial perivasculitis was a prominent feature of the disease process. CLINICAL RELEVANCE: Activated microglia and microglial perivasculitis may play a role in vasculopathy and neuropathy in diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18268214     DOI: 10.1001/archophthalmol.2007.65

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  146 in total

Review 1.  Inflammation in diabetic retinopathy.

Authors:  Johnny Tang; Timothy S Kern
Journal:  Prog Retin Eye Res       Date:  2011-05-25       Impact factor: 21.198

Review 2.  Stemming vision loss with stem cells.

Authors:  Valentina Marchetti; Tim U Krohne; David F Friedlander; Martin Friedlander
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

3.  Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy.

Authors:  Christopher H Gibbons; Roy Freeman
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 4.  Diabetic retinopathy is a neurodegenerative disorder.

Authors:  Stephanie K Lynch; Michael D Abràmoff
Journal:  Vision Res       Date:  2017-04-28       Impact factor: 1.886

Review 5.  Long-term control of neuropathic pain in a non-viral gene therapy paradigm.

Authors:  E M Sloane; R G Soderquist; S F Maier; M J Mahoney; L R Watkins; E D Milligan
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

6.  Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study.

Authors:  Catherine A Cukras; Philip Petrou; Emily Y Chew; Catherine B Meyerle; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-22       Impact factor: 4.799

7.  Erianin alleviates diabetic retinopathy by reducing retinal inflammation initiated by microglial cells via inhibiting hyperglycemia-mediated ERK1/2-NF-κB signaling pathway.

Authors:  Tianyu Zhang; Hao Ouyang; Xiyu Mei; Bin Lu; Zengyang Yu; Kaixian Chen; Zhengtao Wang; Lili Ji
Journal:  FASEB J       Date:  2019-07-31       Impact factor: 5.191

8.  Insulin treatment normalizes retinal neuroinflammation but not markers of synapse loss in diabetic rats.

Authors:  Dustin R Masser; Heather D VanGuilder Starkey; Georgina V Bixler; Wendy Dunton; Sarah K Bronson; Willard M Freeman
Journal:  Exp Eye Res       Date:  2014-06-12       Impact factor: 3.467

9.  Neural inflammation and the microglial response in diabetic retinopathy.

Authors:  Steven F Abcouwer
Journal:  J Ocul Biol Dis Infor       Date:  2012-04-24

10.  Subconjunctivally Implanted Hydrogels for Sustained Insulin Release to Reduce Retinal Cell Apoptosis in Diabetic Rats.

Authors:  Hisanori Imai; Gauri P Misra; Linfeng Wu; Dileep R Janagam; Thomas W Gardner; Tao L Lowe
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.